Unexpected reduction of ethyl 3-phenylquinoxaline-2-carboxylate 1,4-Di-N-oxide derivatives by amines

Article abstract of DOI:10.3390/molecules13010078

The unexpected tendency of amines and functionalized hydrazines to reduce ethyl 3-phenylquinoxaline-2-carboxylate 1,4-di-N-oxide (1) to afford a quinoxaline 1c and mono-oxide quinoxalines 1a and 1b is described. The experimental conditions were standardiz

Full text of DOI:10.3390/molecules13010078

Molecules 2008, 13, 78-85
molecules
ISSN 1420-3049
© 2008 by MDPI
www.mdpi.org/molecules
Full Paper
Unexpected Reduction of Ethyl 3-Phenylquinoxaline-2-
carboxylate 1,4-Di-N-oxide Derivatives by Amines†
Lidia M. Lima 1,2, Esther Vicente 1, Beatriz Solano 1, Silvia Pérez-Silanes 1, Ignacio Aldana 1,*
and Antonio Monge 1
1
Unidad de Investigación y Desarrollo de Medicamentos, Centro de Investigación en
Farmacobiología Aplicada (CIFA), University of Navarra, 31080 Pamplona, Spain
2
Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Faculdade de Farmácia,
Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, PO Box 68024, RJ 21944-970,
Brazil
† Initial data presented at the 11th International Electronic Conference on Synthetic Organic Chemistry,
ECSOC-11, http://www.usc.es/congresos/ecsoc/11/ECSOC11.htm, 1-30 November 2007, paper
a029
* Author to whom correspondence should be addressed. E-mail: ialdana@unav.es
Received: 21 December 2007; in revised form: 16 January 2008 / Accepted: 16 January 2008 /
Published: 17 January 2008
Abstract: The unexpected tendency of amines and functionalized hydrazines to reduce
ethyl 3-phenylquinoxaline-2-carboxylate 1,4-di-N-oxide (1) to afford a quinoxaline 1c and
mono-oxide quinoxalines 1a and 1b is described. The experimental conditions were
standardized to the use of two equivalents of amine in ethanol under reflux for two hours,
with the aim of studying the distinct reductive profiles of the amines and the
chemoselectivity of the process. With the exception of hydrazine hydrate, which reduced
compound 1 to a 3-phenyl-2-quinoxalinecarbohydrazide derivative, the amines only acted
as reducing agents.
Keywords: Quinoxaline N-oxides, reduction, carboxylate, amines.

Molecules 2008, 13
79
Introduction
Quinoxaline and quinoxaline 1,4-di-N-oxide are heterocycles that are often used in the synthesis of
biologically active compounds [1-31]. The former is described as a bioisoster of the quinoline,
naphthyl, benzothienyl and other aromatic rings [32], and it can be found in the structure of anti-
bacterial [1], anti-tuberculosis [5-7, 9-11, 13, 14, 16, 22], anti-cancer [8, 18, 20, 28], anti-malarial [12,
24, 26, 29-31], anti-Chagas [15, 25] and anti-inflammatory [19, 27] drug candidates. The widespread
activity of quinoxaline 1,4-di-N-oxides can be associated with the generation of free radicals [33]. In
our continuing efforts to find quinoxaline-1,4-di-N-oxide derivatives with anti-malarial activity [12,
23, 24, 26, 29-31], the conversion of compound 1 into hydrazides 2 and amide derivatives 3 was
carried out by means of hydrazinolysis and aminolysis reactions, in which unexpected results were
obtained. In this work we describe the reducing profiles of amine derivatives when they act upon the
ethyl 3-phenylquinoxaline-2-carboxylate 1,4-di-N-oxide derivative 1.
Scheme 1. Design of new quinoxaline 1,4-di-N-oxide derivatives.
O
N+
O
O
N+
O
NHR
N
O
CH3
H
N+
O
N+
O
search for alternative
isosteric groups
(2)
(1)
R=Ph, Me
IC50= >10 μM
anti-malarial
O
N+
O
R1
N
H
N+
O
(3)
R1=OH, CH3, CH2OH
Results and Discussion
In a continuing effort to synthesize new anti-malarial drug candidates, we wished to substitute the
carboethoxy moiety present in lead-compound 1, with a functionalized hydrazide subunit 2 (Scheme
1). For this purpose compound 1 was first treated with phenylhydrazine in the presence of ethanol
under reflux for two hours. After workup, the crude oil was analyzed by 1H-NMR, which revealed the
presence of four different carboethoxy group signals. This crude oil was purified by silica gel column
1
chromatography and the separated products analyzed by H-NMR, IR, mass spectra and elemental
analyses. From these analyses, it was observed that the reaction with phenylhydrazine had failed to
produce the functionalized hydrazide derivative 2, but rather this reaction surprisingly gave a mixture
of quinoxaline 1c, quinoxalines N-4 monoxide 1a, N-1 monoxide 1b and 1,4-di-N-oxide 1 (Table 1).
While the reducing activity of hydrazine hydrate [34, 35] is well known, the aforementioned
information was not as clear for phenylhydrazine. In an attempt to determine if the reduction of 1 by
phenylhydrazine could be influenced by the electronic profile of quinoxaline-ester 1, the derivatives 4-
7, attached to electron-withdrawing and electron-donating groups, were treated with phenylhydrazine
in ethanol under reflux for two hours; the results are given in Table 1 (entries 2, 3, 4 and 5). These
results showed no selective reduction for substrates 5-7, with the exception of compound 4 (4’-nitro,

Molecules 2008, 13
80
σp = 0.81) that could be selectively reduced to quinoxaline 4c (entry 2). In this particular case,
different reducing profiles were observed for phenylhydrazine and hydrazine hydrate because, with the
latter no chemoselectivity was observed, and consequently, the nitro group was also reduced and the
hydrazinolysis product was formed (data not shown). Intrigued by these results, the possibility that
other amines could act as reducing agents towards the quinoxaline 1,4-di-N-oxide system was then
studied. Derivative 1, used as template, was treated with different amines (two equivalents) in the
presence of ethanol under reflux for two hours (Table 1). The results clearly demonstrated the ability
of hydroxylamine (entry 9), methylamine (entry 10), ethanolamine (entry 11), methyl hydrazine (entry
6), and 2,4-dinitrophenylhydrazine (entry 7) to reduce compound 1 to the mono-oxide derivatives 1a
and 1b and to quinoxaline 1c, while amines such as triethylamine (entry 12) and aniline (entry 13),
were unable to reduce compound 1, as no significant difference was noted when compared to the
experiment carried out in the absence of amine (entry 14).
Table 1: Reduction of ethyl 3-phenylquinoxaline-2-carboxylate 1,4-di-N-oxide (1).
(O)n O
N+
O
O
N+
O
CH3
W
O
CH3
W
amine (2 eq.)/EtOH
reflux/2h
N+
N+
O
(1, 4-7)
(O)n1
W= H (1);
W= NO2 (4);
n=0, n1= 1 (a)
n=1, n1= 0 (b)
n= n1= 0 (c)
W= CF3 (5);
W= OCH3 (6);
W= CH3 (7).
n=n1=1
n=0, n1=1 n=1, n1=0
n=n1=0
Entry
Reducing Agent
W
(1, 4-7)
18.1%
16.7%
22.6%
25.7%
15.1%
43.8%
57.4%
0%
(1b, 4-7a) (1c, 4-7b) (1a, 4-7c)
1
2
PhNHNH2
PhNHNH2
PhNHNH2
PhNHNH2
PhNHNH2
H3CNHNH2
H
NO2
CF3
OCH3
CH3
H
30.1%
0%
28.4%
0%
23.4%
83.3%
23.7%
28.1%
31.2%
11.9%
9.6%
100%*
35.5%
8.5%
29.8%
0%
3
30,0%
28.6%
31.8%
21.8%
8.9%
0%
23.7%
17.6%
21.9%
22.5%
24.1%
0%
4
5
6
7
2,4-diNO2PhNHNH2
N2H4.H2O
NH2OH.H2O
NH2CH3.H2O
NH2(CH2)2OH
Et3N
H
8
H
9
H
22.6%
33.8%
0%
8.1%
8.0%
34.2%
0%
33.8%
49.7%
36.0%
19.2%
18.8%
14.5%
0%
10
11
12
13
14
15
16
H
H
H
80.8%
81.2%
85.5%
0%
PhNH2
H
0%
0%
EtOH
H
0%
0%
P(OCH3)3
Na2S2O4
H
100%
0%
0%
H
0%
0%
100%
*formation of 3-phenyl-2-quinoxalinecarbohydrazide; absence of chemioselectivity.
The yields were determined by 1H-NMR analysis of total crude product mixtures obtained after the
work-up of each reaction. The methyl (OCH2CH3) resonances for the four compounds 1, 1a, 1b and
1c, were observed at different chemical shifts, and thus, integration of the methyl region (OCH2CH3)

Molecules 2008, 13
81
allowed relative molar percentages to be readily ascertained. The unequivocal structural assignments
of the N-4 oxide 1a, N-1 oxide 1b and quinoxaline 1c derivatives were accomplished by 1H-NMR, IR,
mass spectra and elemental analyses. In an attempt to specifically identify mono-oxide quinoxaline
derivatives (1a versus 1b), a selective mono-deoxygenation of compound 1 was performed (entry 14)
using trimethylphosphite (entry 15), as previously described by Kluge and coworkers [36]. By this
methodology, it was only possible to obtain the N-4 oxide derivative 1a, which was characterized by
1H-NMR; the data was used for direct comparison with the N-oxides obtained from the reaction with
the amines. In a similar way, the quinoxaline di-N-oxide 1 was totally reduced to quinoxaline 1c, using
Na2S2O4 (entry 16) in a mixture of methanol and water [37, 24]; the chemical shift of compound 1c
1
was measured by H-NMR and compared with the products obtained from amine reductions.
Compounds 1a, 1b and 1c were evaluated for their ability to inhibit P. falciparum (chloroquine
sensitive), and were shown to be inactive as anti-malarial agents (data not shown).
Conclusions
In summary, this work clearly demonstrates a tendency of amines and functionalized hydrazines to
reduce ethyl 3-phenylquinoxaline-2-carboxylate 1,4-di-N-oxide (1) to a quinoxaline 1c and mono-
oxides quinoxalines 1a and 1b. Although the starting material 1 was recovered in most of the reactions
(entries 1-7, 9-10, 12-14), suggesting that a longer time reaction could be necessary, the experimental
conditions were standardized in two hours, using two equivalents of amine, with the aim of studying
the distinct reductive profile of the amine used and the chemoselectivity of the process. With the
exception of hydrazine hydrate, a well-known reducing agent, which reduced compound 1 to a 3-
phenyl-2-quinoxalinecarbohydrazide derivative, the amines were unable to act as nucleophiles and
acted exclusively as reducing agents. Compounds 1a, 1b and 1c were inactive as antimalarial agents.
Experimental
General
All of the synthesized compounds were chemically characterized by thin layer chromatography
(TLC), infrared (IR), nuclear magnetic resonance (1H-NMR), mass spectra (MS) and elemental
microanalysis (CHN). Alugram SIL G/UV254 (0.2 mm layer, Macherey-Nagel GmbH & Co. KG.
Düren, Germany) was used for TLC and Silica gel 60 (0.040-0.063 mm, Merck) for Flash Column
Chromatography. 1H-NMR spectra were recorded on a Bruker 400 Ultrashield instrument (400 MHz),
using TMS as the internal standard with CDCl3 as the solvent; the chemical shifts are reported in ppm
(δ) and coupling constants (J) values are given in Hertz (Hz). Signal multiplicities are represented by:
s (singlet), d (doublet), t (triplet), q (quadruplet), dd (double doublet) and m (multiplet). IR spectra
were recorded on a Nicolet Nexus FTIR (Thermo, Madison, USA) in KBr pellets. Mass spectra were
measured on a MSD/DS 5973N G2577A mass spectrometer (Agilent Technologies, Waldbronn,
Germany) with a direct insertion probe (DIP). The ionization method was electron impact (EI, 70 eV).
Elemental microanalyses were obtained on a Leco CHN-900 Elemental Analyzer (Leco, Tres Cantos,
Spain) from vacuum-dried samples. The analytical results for C, H, and N, were within ± 0.4 of the

Molecules 2008, 13
82
theoretical values. Chemicals were purchased from Panreac Química S.A. (Barcelona, Spain), Sigma-
Aldrich Química, S.A. (Alcobendas, Spain), Acros Organics (Janssen Pharmaceuticalaan, Geel,
Belgium) and Lancaster (Bischheim-Strasbourg, France).
General procedure for the reduction of ethyl 3-phenylquinoxaline-2-carboxylate 1,4-di-N-oxide (1)
Ethyl 3-phenylquinoxaline-2-carboxylate 1,4-di-N-oxide (1, 1 mmol) was added to ethanol (10
mL) and the amine derivative (1 mmol). The mixture was refluxed for two hours, then the reactions
were worked-up by adding CH2Cl2 (50 mL), followed by extraction with 10% aqueous HCl (4 x 15
mL). The organic layer was dried (Na2SO4), filtered, and evaporated to dryness. The yields were
1
determined by H-NMR analysis of the total crude product mixture. The residue was later purified by
silica gel column chromatography (n-hexane-ethyl acetate).
1
Ethyl 3-phenylquinoxaline-2-carboxylate 1,4-di-N-oxide (1). H-NMR: δ 1.08 (t, J= 7.2 Hz, 3H,
OCH2CH3); 4.25 (t, J= 7.2 Hz, 2H, OCH2CH3); 7.53 (m, 3H, H3’-H5’); 7.61 (m, 2H, H2’ and H6’);
13
7.91 (m, 2H, H6 and H7); 8.65 (m, 2H, H5 and H8) ppm; C-NMR: δ 13.98 (OCH2CH3), 63.65
(OCH2CH3), 120.89 (C5), 121.08 (C8), 127.84 (C1’), 129.16 (C3’ and C5’), 130.15 (C2’ and C6’),
131.26 (C4’), 132.51 (C6), 132.53 (C7), 136.53 (C2), 137.73 (C10), 138.81 (C3), 140.08 (C9), 159.66
(CO2Et) ppm; IR: 2978 (ArC-H), 1746 (C=O), 1352 (N-oxide), 701 and 666 (monosubstituted phenyl)
cm-1; MS: 310 (m/z, 100%), 294 (M+, 6%), 249 (M+, 51%), 221 (M+, 46%), 77 (M+, 46%); Anal.
calcd. for C17H14N2O4: C, 65.80; H, 4.52; N, 9.03. Found: C, 65.65; H, 4.57; N, 8.98.
1
Ethyl 3-phenylquinoxaline-2-carboxylate 4-N-oxide (1a). H-NMR: δ 1.04 (t, J=7.2 Hz; 3H,
OCH2CH3); 4.20 (q, J=7.2 Hz; 2H, OCH2CH3); 7.56 (m, 3H, H3’-H5’); 7.61 (m, 2H, H2’and H6’);
7.88 (m, 2H, H6 and H7); 8.26 (dd, J= 1.2, 8.2 Hz; 1H, H5); 8.65 (dd, J= 1.2, 7.6 Hz; 1H, H8); IR:
2981 (ArC-H), 1742 (C=O), 1359 (N-oxide), 701 and 666 (monosubstituted phenyl) cm-1; MS: 294
(m/z, 65%), 265 (M+, 13%), 249 (M+, 26%), 221 (M+, 100%), 77 (M+, 18%); Anal. calcd. for
C17H14N2O3: C, 69.38; H, 4.79; N, 9.52. Found: C, 69.37; H, 4.77; N, 9.51.
1
Ethyl 3-phenylquinoxaline-2-carboxylate 1-N-oxide (1b). H-NMR: δ 1.25 (t, J=7.2 Hz; 3H,
OCH2CH3); 4.42 (q, J=7.2 Hz; 2H, OCH2CH3); 7.54 (m, 3H, H3’-H5’); 7.80 (m, 3H, H2’and H6’ and
H7); 7.89 (dt, J= 8.4, 7.6 Hz; 1H, H6); 8.20 (d, J= 8.4 Hz; 1H, H5); 8.61 (d, J= 8.0 Hz; 1H, H8); IR
(KBr): 2979 (ArC-H), 1735 (C=O), 1363 (N-oxide), 701 and 671 (monosubstituted phenyl) cm-1; MS:
294 (m/z, 60%), 265 (M+, 9%), 249 (M+, 31%), 221 (M+, 100%), 77 (M+, 26%); Anal. calcd. for
C17H14N2O3: C, 69.38; H, 4.79; N, 9.52. Found: C, 69.39; H, 4.80; N, 9.51.
Ethyl 3-phenylquinoxaline-2-carboxylate (1c). 1H-NMR: δ 1.19 (t, J=7.2 Hz; 3H, OCH2CH3); 4.34 (q,
J=7.2 Hz; 2H, OCH2CH3); 7.53 (m, 3H, H3’-H5’); 7.76 (m, 2H, H2’and H6’); 7.85 (m, 2H, H6 and
H7); 8.20 (d, J= 8.0 Hz; 1H, H5); 8.24 (d, J= 7.6 Hz; 1H, H8); IR: 2990 (ArC-H), 1730 (C=O), 711
and 669 (monosubstituted phenyl) cm-1; MS: 278 (m/z, 33%), 249 (M+, 26%), 234 (M+, 15%), 206
(M+, 100%), 77 (M+, 33%); Anal. calcd. for C17H14N2O2: C, 73.37; H, 5.07; N, 10.07. Found: C, 73.35;
H, 5.08; N, 10.05.

Molecules 2008, 13
83
Acknowledgements
This work has been carried out with the financial support of the FIS project (1051005, October
2005), the Instituto de Salud Carlos III: Red de centros de cancer RTICCC (C03/10) and the PiUNA
project (University of Navarra). We also thank the “Coordenação de Aperfeiçoamento de Pessoal de
Nível Superior” (CAPES; BR) for the fellowship (to LML; BEX0520/04-7) received.
References
1. Dirlam, J. P.; Presslitz, J. E. Synthesis and antibacterial activity of isomeric 6 and 7-acetyl-3-
methyl-2-quinoxalinecarboxamide 1,4-dioxides. J. Med. Chem. 1978, 21, 483-485.
2. Dirlam, J. P.; Czuba, L. J.; Dominy, B. W.; James, R. B.; Pezzullo, R. M.; Presslitz, J. E.;
Windisch, W. W. Synthesis and antibacterial activity of 1-hydroxy-1-methyl-1,3-dihydrofuro[3,4-
b]quinoxaline 4,9-dioxide and related compounds. J. Med. Chem. 1979, 22, 1118-1121.
3. Monge, A.; Martinez-Crespo, F. J.; De Cerain, A. L.; Palop, J. A.; Narro, S.; Senador, V.; Marin,
A.; Sainz, Y.; Gonzalez, M.; Hamilton, E.; Barker, A. J. Hypoxia-selective agents derived from 2-
quinoxalinecarbonitrile 1,4-di-N-oxides. 2. J. Med. Chem. 1995, 38, 4488-4494.
4. Monge, A.; Palop, J. A.; De Cerain, A. L.; Senador, V.; Martinez-Crespo, F. J.; Sainz, Y.; Narro,
S.; Garcia, E.; De Miguel, C.; Gonzalez, M.; Hamilton, E.; Barker, A. J.; Clarke, E. D.;
Greenhow, D. T. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides. J. Med.
Chem. 1995, 38, 1786-1792.
5. Montoya, M. E.; Sainz, Y.; Ortega, M. A.; De Cerain, A. L.; Monge, A. Synthesis and
antituberculosis activity of some new 2-quinoxalinecarbonitriles. Farmaco 1998, 53, 570-573.
6. Ortega, M. A.; Sainz, Y.; Montoya, M. E.; De Cerain, A. L.; Monge, A. Synthesis and
antituberculosis activity of new 2-quinoxalinecarbonitrile 1,4-di-N-oxides. Pharmazie 1999, 54,
24-25.
7. Sainz, Y.; Montoya, M. E.; Martinez-Crespo, F. J.; Ortega, M. A.; de Cerain, A. L.; Monge, A.
New quinoxaline 1,4-di-N-oxides for treatment of tuberculosis. Arzneim.-Forsch. 1999, 49, 55-59.
8. Ortega, M. A.; Morancho, M. J.; Martinez-Crespo, F. J.; Sainz, Y.; Montoya, M. E.; de Cerain, A.
L.; Monge, A. New quinoxalinecarbonitrile 1,4-di-N-oxide derivatives as hypoxic-cytotoxic
agents. Eur. J. Med. Chem. 2000, 35, 21-30.
9. Ortega, M. A.; Montoya, M. E.; Jaso, A.; Zarranz, B.; Tirapu, I.; Aldana, I.; Monge, A.
Antimycobacterial activity of new quinoxaline-2-carbonitrile and quinoxaline-2-carbonitrile 1,4-
di-N-oxide derivatives. Pharmazie 2001, 56, 205-207.
10. Carta, A.; Paglietti, G.; Rahbar Nikookar, M. E.; Sanna, P.; Sechi, L.; Zanetti, S. Novel
substituted quinoxaline 1,4-dioxides with in vitro antimycobacterial and anticandida activity. Eur.
J. Med. Chem. 2002, 37, 355-366.
11. Ortega, M. A.; Sainz, Y.; Montoya, M. E.; Jaso, A.; Zarranz, B.; Aldana, I.; Monge, A. Anti-
Mycobacterium tuberculosis agents derived from quinoxaline-2-carbonitrile and quinoxaline-2-
carbonitrile 1,4-di-N-oxide. Arzneim.-Forsch. 2002, 52, 113-119.

Molecules 2008, 13
84
12. Aldana, I.; Ortega, M. A.; Jaso, A.; Zarranz, B.; Oporto, P.; Gimenez, A.; Monge, A.; Deharo, E.
Anti-malarial activity of some 7-chloro-2-quinoxalinecarbonitrile-1,4-di-N-oxide derivatives.
Pharmazie 2003, 58, 68-69.
13. Jaso, A.; Zarranz, B.; Aldana, I.; Monge, A. Synthesis of new 2-acetyl and 2-benzoyl quinoxaline
1,4-di-N-oxide derivatives as anti-Mycobacterium tuberculosis agents. Eur. J. Med. Chem. 2003,
38, 791-800.
14. Zarranz, B.; Jaso, A.; Aldana, I.; Monge, A. Synthesis and antimycobacterial activity of new
quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives. Bioorg. Med. Chem. 2003, 11, 2149-2156.
15. Aguirre, G.; Cerecetto, H.; Di Maio, R.; Gonzalez, M.; Alfaro, M. E. M.; Jaso, A.; Zarranz, B.;
Ortega, M. A.; Aldana, I.; Monge-Vega, A. Quinoxaline N,N'-dioxide derivatives and related
compounds as growth inhibitors of Trypanosoma cruzi. Structure-activity relationships. Bioorg.
Med. Chem. Lett. 2004, 14, 3835-3839.
16. Carta, A.; Loriga, M.; Paglietti, G.; Mattana, A.; Fiori, P. L.; Mollicotti, P.; Sechi, L.; Zanetti, S.
Synthesis, anti-mycobacterial, anti-trichomonas and anti-candida in vitro activities of 2-
substituted-6,7-difluoro-3-methylquinoxaline 1,4-dioxides. Eur. J. Med. Chem. 2004, 39, 195-
203.
17. Kim, Y. B.; Kim, Y. H.; Park, J. Y.; Kim, S. K. Synthesis and biological activity of new
quinoxaline antibiotics of echinomycin analogues. Bioorg. Med. Chem. Lett. 2004, 14, 541-544.
18. Perez-Melero, C.; Maya, A. B.; del Rey, B.; Pelaez, R.; Caballero, E.; Medarde, M. A new family
of quinoline and quinoxaline analogues of combretastatins. Bioorg. Med. Chem. Lett. 2004, 14,
3771-3774.
19. Singh, S. K.; Saibaba, V.; Ravikumar, V.; Rudrawar, S. V.; Daga, P.; Rao, C. S.; Akhila, V.;
Hegde, P.; Rao, Y. K. Synthesis and biological evaluation of 2,3-diarylpyrazines and quinoxalines
as selective COX-2 inhibitors. Bioorg. Med. Chem. 2004, 12, 1881-1893.
20. Zarranz, B.; Jaso, A.; Aldana, I.; Monge, A. Synthesis and anticancer activity evaluation of new
2-alkylcarbonyl and 2-benzoyl-3-trifluoromethyl-quinoxaline 1,4-di-N-oxide derivatives. Bioorg.
Med. Chem. 2004, 12, 3711-3721.
21. Carta, A.; Corona, P.; Loriga, M. Quinoxaline 1,4-dioxide: A versatile scaffold endowed with
manifold activities. Curr. Med. Chem. 2005, 12, 2259-2272.
22. Jaso, A.; Zarranz, B.; Aldana, I.; Monge, A. Synthesis of new quinoxaline-2-carboxylate 1,4-
dioxide derivatives as anti-Mycobacterium tuberculosis agents. J. Med. Chem. 2005, 48, 2019-
2025.
23. Lima, L. M.; Zarranz, B.; Marin, A.; Solano, B.; Vicente, E.; Silanes, S. P.; Aldana, I.; Monge, A.
Comparative use of solvent-free KF-Al2O3 and K2CO3 in acetone in the synthesis of quinoxaline
1,4-dioxide derivatives designed as antimalarial drug candidates. J. Heterocycl. Chem. 2005, 42,
1381-1385.
24. Zarranz, B.; Jaso, A.; Aldana, I.; Monge, A.; Maurel, S.; Deharo, E.; Jullian, V.; Sauvain, M.
Synthesis and antimalarial activity of new 3-arylquinoxaline-2-carbonitrile derivatives. Arzneim.-
Forsch. 2005, 55, 754-761.
25. Urquiola, C.; Vieites, M.; Aguirre, G.; Marin, A.; Solano, B.; Arrambide, G.; Noblia, P.; Lavaggi,
M. L.; Torre, M. H.; Gonzalez, M.; Monge, A.; Gambino, D.; Cerecetto, H. Improving anti-

Molecules 2008, 13
85
trypanosomal activity of 3-aminoquinoxaline-2-carbonitrile N1,N4-dioxide derivatives by
complexation with vanadium. Bioorg. Med. Chem. 2006, 14, 5503-5509.
26. Zarranz, B.; Jaso, A.; Lima, L. M.; Aldana, I.; Monge, A.; Maurel, S.; Sauvain, M.
Antiplasmodial activity of 3-trifluoromethyl-2-carbonylquinoxaline di-N-oxide derivatives. Braz.
J. Pharm. Sci. 2006, 42, 357-361.
27. Burguete, A.; Pontiki, E.; Hadjipavlou-Litina, D.; Villar, R.; Vicente, E.; Solano, B.; Ancizu, S.;
Perez-Silanes, S.; Aldana, I.; Monge, A. Synthesis and anti-inflammatory/antioxidant activities of
some new ring substituted 3-phenyl-1-(1,4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one
derivatives and of their 4,5-dihydro-(1H)-pyrazole analogues. Bioorg. Med. Chem. Lett. 2007, 17,
6439-6443.
28. Solano, B.; Junnotula, V.; Marín, A.; Villar, R.; Burguete, A.; Vicente, E.; Pérez-Silanes, S.;
Aldana, I.; Monge, A.; Dutta, S.; Sarkar, U.; Gates, K. S. Synthesis and biological evaluation of
new 2-arylcarbonyl-3-trifluoromethylquinoxaline 1,4-di-N-oxide derivatives and their reduced
analogs. J. Med. Chem. 2007, 50, 5485-5492.
29. Marín, A.; Lima, L. M.; Solano, B.; Vicente, E.; Pérez-Silanes, S.; Maurel, S.; Sauvain, M.;
Aldana, I.; Monge, A.; Deharo, E. Antiplasmodial structure-activity relationship of 3-trifluoro-
methyl-2-arylcarbonylquinoxaline 1,4-di-N-oxide derivatives. Exp. Parasitol. 2008, 118, 25-31.
30. Vicente, E.; Charnaud, S.; Bongard, E.; Villar, R.; Burguete, A.; Solano, B.; Ancizu, S.; Pérez-
Silanes, S.; Aldana, I.; Vivas, L.; Monge, A. Synthesis and antiplasmodial activity of 3-furyl and
3-thienylquinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives. Molecules 2008, 13, 69-77.
31. Vicente, E.; Lima, L. M.; Bongard, E.; Charnaud, S.; Villar, R.; Solano, B.; Burguete, A.; Pérez-
Silanes, S.; Aldana, I.; Vivas, L.; Monge, A. Synthesis and structure-activity relationship of 3-
phenylquinoxaline 1,4-di-N-oxide derivatives as antimalarial agents. Eur. J. Med. Chem. 2008,
doi: 10.1016/j.ejmech.2007.1011.1024. In Press.
32. Lima, L. M.; Barreiro, E. J. Bioisosterism: A useful strategy for molecular modification and drug
design. Curr. Med. Chem. 2005, 12, 23-49.
33. Inbaraj, J. J.; Motten, A. G.; Chignell, C. F. Photochemical and photobiological studies of
tirapazamine (SR 4233) and related quinoxaline 1,4-di-N-oxide analogues. Chem. Res. Toxicol.
2003, 16, 164-170.
34. Kuhn, L. P. Catalytic reduction with hydrazine. J. Am. Chem. Soc. 1951, 73, 1510-1512.
35. Abul-Hajj, Y. J. Stereospecific reduction of steroidal 4-ene-3-ols with hydrazine. J. Org. Chem.
1971, 36, 2730.
36. Kluge, A. F.; Maddox, M. L.; Lewis, G. S. Formation of quinoxaline monoxides from reaction of
benzofurazan oxide with enones and C-13 NMR correlations of quinoxaline N-oxides. J. Org.
Chem. 1980, 45, 1909-1914.
37. Haddadin, M. J.; Zahr, G. E.; Rawdah, T. N.; Chelhot, N. C.; Issidorides, C. H. Deoxygenation of
quinoxaline N-oxides and related compounds. Tetrahedron 1974, 30, 659-666.
Sample avalibility: Contact the authors
© 2008 by MDPI (http://www.mdpi.org). Reproduction is permitted for noncommercial purposes.